As a result, this agent was further evaluated in several clinical trials for various diseases, including asthma, bronchial asthma and noncystic fibrosis bronchiectasis, demonstrating also a lower incidence of possible adverse effects in comparison to early developed PDE4 inhibitors [40]. Here, PDE4A is linked to asthma.